Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Renal Cell 2Zollinger-Ellison Syndrome 1Uterine Cervical Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1Carcinoma, Hepatocellular 1Blast Crisis 1Adenoma, Islet Cell 1

Interventions

Temozolomide 6Capecitabine 4Everolimus 3Thalidomide 2Sunitinib 2Streptozocin 2Octreotide 2Injections 2Fluorouracil 2surufatinib 1sargramostim 1recombinant interferon alpha 2b-like protein 1nimotuzumab 1motesanib diphosphate 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1Tegafur 1Specimen Handling 1PM 01183 1Metformin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenoma, Islet Cell × Interferons × Clear all
NCT00001228 2017-07-02

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled

Adenoma, Islet Cell, Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡